South America ECMO Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)

List of Tables

The South America ECMO market is expected to grow from US$ 53.00 million in 2022 to US$ 60.58 million by 2028. It is estimated to record a CAGR of 2.3% from 2022 to 2028.

Growing Adoption of ECMO in Lung Transplantation Procedures Bolsters South America ECMO Market Growth

Lung transplantation is a life-saving treatment option for patients suffering from end-stage lung diseases, such as COPD, Idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, to improve the quality of life. ECMO is a versatile tool used in all lung transplantation phases, such as preoperative, intraoperative, and postoperative periods. It acts as a bridge in patient undergoing lung transplantation. Therefore, the adoption of ECMO during lung transplantation is growing rapidly to manage patients with life-threatening lung disease. Primary graft dysfunction (PGD) is the leading cause of death after a lung transplant. Thus, ECMO is used penultimately in treating PGD post lung transplantation. Thus, the demand for ECMO equipment is growing for treating the patients suffering from PGD.

South America ECMO Market Overview

The SAM ECMO market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022. According to World Heart Federation, noncommunicable diseases such as cardiovascular disease accounts for 74% of total deaths in Brazil. According to Global Burden Study (GBD) and Brazilian Unified Health System, cardiovascular disease was the leading cause of death in Brazil in 2019. Due to the increasing aging population in Brazil, the prevalence of cardiovascular diseases is increasing each year. According to GBD, the number of ischemic heart disease (IHD) cases reached 4 million in 2019. Further, about 171,246 deaths were reported due to IHD, which accounted for 43% of cardiovascular deaths and 12% of total deaths in Brazil in 2019. Thus, growing cardiovascular disease cases in Brazil are driving the ECMO market growth in the country.

South America ECMO Market Revenue and Forecast to 2028 (US$ Million)

South America ECMO Market Segmentation

The South America ECMO market is segmented based on modality, application, age group, and country.

Based on modality, the SAM ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.

Based on application, the SAM ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.

Based on age group, the SAM ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.

Based on country, the SAM ECMO market has been categorized into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Brazil dominated the market in 2022.

ABIOMED Inc, Braile Biomedica, Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the SAM ECMO market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the SAM ECMO market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the SAM ECMO market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth SAM market trends and outlook coupled with the factors driving the ECMO market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00027974

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 SAM ECMO Market - By Modality
- 1.3.2 SAM ECMO Market - By Application
- 1.3.3 SAM ECMO Market - By Age Group
- 1.3.4 SAM ECMO Market - By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. SAM ECMO Market - Market Landscape

4.1 Overview
4.2 SAM PEST Analysis
4.3 Experts Opinion

5. SAM ECMO Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Prevalence of Cardiovascular Diseases and Respiratory Failures
- 5.1.2 Growing Adoption of ECMO in Lung Transplantation Procedures
5.2 Market Restraints
- 5.2.1 Complications Associated with ECMO
5.3 Market Opportunities
- 5.3.1 Increasing Survival Rates with ECMO
5.4 Future Trends
- 5.4.1 Surging Product Developments and Approvals
5.5 Impact Analysis

6. ECMO Market - SAM Analysis

6.1 SAM ECMO Market Revenue Forecast & Analysis

7. SAM ECMO Market Analysis - By Modality

7.1 Overview
7.2 SAM ECMO Market Share by Modality 2021 & 2028 (%)
7.3 Venoarterial ECMO
- 7.3.1 Overview
- 7.3.2 Venoarterial ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)
7.4 Venovenous ECMO
- 7.4.1 Overview
- 7.4.2 Venovenous ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)
7.5 Arteriovenous ECMO
- 7.5.1 Overview
- 7.5.2 Arteriovenous ECMO: ECMO Market Revenue and Forecast to 2028 (US$ Million)

8. SAM ECMO Market Analysis - By Application

8.1 Overview
8.2 SAM ECMO Market, By Application 2021 & 2028 (%)
8.4 Respiratory
- 8.4.1 Overview
- 8.4.2 Respiratory Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Cardiology
- 8.5.1 Overview
- 8.5.2 Cardiology Market Revenue and Forecast to 2028 (US$ Mn)

9. SAM ECMO Market Analysis - By Age Group

9.1 Overview
9.2 SAM ECMO Market, By Age Group 2021 & 2028 (%)
9.3 Adults
- 9.3.1 Overview
- 9.3.2 Adults Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Pediatrics
- 9.4.1 Overview
- 9.4.2 Pediatrics Market Revenue and Forecast to 2028 (US$ Mn)
9.5 Neonates
- 9.5.1 Overview
- 9.5.2 Neonates Market Revenue and Forecast to 2028 (US$ Mn)

10. SAM ECMO Market - Country Analysis

10.1 Overview
- 10.1.1 SAM: ECMO, by Country, 2021 & 2028 (%)
  - 10.1.1.1 Brazil: ECMO - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.1.1 Overview
    - 10.1.1.1.2 Brazil: ECMO - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.1.3 Brazil: ECMO, by Modality, 2019-2028 (US$ Million)
    - 10.1.1.1.4 Brazil: ECMO, by Application, 2019-2028 (US$ Million)
    - 10.1.1.1.5 Brazil: ECMO, by Age Group, 2019-2028 (US$ Million)
  - 10.1.1.2 Argentina: ECMO - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 Argentina: ECMO - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.2.3 Argentina: ECMO, by Modality, 2019-2028 (US$ Million)
    - 10.1.1.2.4 Argentina: ECMO, by Application, 2019-2028 (US$ Million)
    - 10.1.1.2.5 Argentina: ECMO, by Age Group, 2019-2028 (US$ Million)
  - 10.1.1.3 Rest of SAM: ECMO - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 Rest of SAM: ECMO - Revenue and Forecast to 2028 (US$ Million)
    - 10.1.1.3.3 Rest of SAM: ECMO, by Modality, 2019-2028 (US$ Million)
    - 10.1.1.3.4 Rest of SAM: ECMO, by Application, 2019-2028 (US$ Million)
    - 10.1.1.3.5 Rest of SAM: ECMO, by Age Group, 2019-2028 (US$ Million)

11. Industry Landscape

11.1 Overview
11.2 Inorganic Growth Strategies
- 11.2.1 Overview
11.3 Organic Growth Strategies
- 11.3.1 Overview

12. Company Profiles

12.1 Terumo Group
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Medtronic Plc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 MicroPort Scientific Corporation
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 LivaNova Plc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Nipro Medical Corporation
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Getinge AB
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Braile Biomedica
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Fresenius Medical Care AG & Co KGaA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 ABIOMED Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms